메뉴 건너뛰기




Volumn 15, Issue 8, 2014, Pages 1139-1151

Pharmacotherapy of Hodgkin lymphoma: Standard approaches and future perspectives

Author keywords

Chemotherapy; Hodgkin lymphoma; Positron emission tomography; Radiotherapy; Targeted therapy

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DIHYDROTACHYSTEROL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PANOBINOSTAT; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

EID: 84900810249     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.909411     Document Type: Review
Times cited : (9)

References (68)
  • 2
    • 80052763462 scopus 로고    scopus 로고
    • Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi55-8
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 6
    • Eichenauer, D.A.1    Engert, A.2    Dreyling, M.3
  • 3
    • 0027404777 scopus 로고
    • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
    • Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4
    • (1993) Lancet , vol.341 , pp. 1051-1054
    • Linch, D.C.1    Winfield, D.2    Goldstone, A.H.3
  • 4
    • 0037097044 scopus 로고    scopus 로고
    • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial
    • Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71
    • (2002) Lancet , vol.359 , pp. 2065-2071
    • Schmitz, N.1    Pfistner, B.2    Sextro, M.3
  • 5
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9
    • (2006) Blood , vol.107 , pp. 52-59
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 6
    • 34548486030 scopus 로고    scopus 로고
    • Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study
    • Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52
    • (2007) J Clin Oncol , vol.25 , pp. 3746-3752
    • Gallamini, A.1    Hutchings, M.2    Rigacci, L.3
  • 7
    • 84863688504 scopus 로고    scopus 로고
    • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    • Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7
    • (2012) Nat Biotechnol , vol.30 , pp. 631-637
    • Senter, P.D.1    Sievers, E.L.2
  • 8
    • 84863676500 scopus 로고    scopus 로고
    • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9
    • (2012) J Clin Oncol , vol.30 , pp. 2183-2189
    • Younes, A.1    Gopal, A.K.2    Smith, S.E.3
  • 9
    • 84865189087 scopus 로고    scopus 로고
    • Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin Study Group experience
    • Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012;120:1470-2
    • (2012) Blood , vol.120 , pp. 1470-1472
    • Rothe, A.1    Sasse, S.2    Goergen, H.3
  • 10
    • 84875672985 scopus 로고    scopus 로고
    • Brentuximab vedotin in refractory CD30 + lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
    • Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30 + lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98:611-14
    • (2013) Haematologica , vol.98 , pp. 611-614
    • Gibb, A.1    Jones, C.2    Bloor, A.3
  • 11
    • 34548186696 scopus 로고    scopus 로고
    • Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial
    • Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-502
    • (2007) J Clin Oncol , vol.25 , pp. 3495-3502
    • Engert, A.1    Franklin, J.2    Eich, H.T.3
  • 12
    • 35848959692 scopus 로고    scopus 로고
    • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    • Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27
    • (2007) N Engl J Med , vol.357 , pp. 1916-1927
    • Ferme, C.1    Eghbali, H.2    Meerwaldt, J.H.3
  • 13
    • 77956646155 scopus 로고    scopus 로고
    • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
    • Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52
    • (2010) N Engl J Med , vol.363 , pp. 640-652
    • Engert, A.1    Plutschow, A.2    Eich, H.T.3
  • 14
    • 78149436503 scopus 로고    scopus 로고
    • Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: Results of the second interim analysis of the GHSG HD13 trial
    • Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica 2010;95(Suppl 2):A1146
    • (2010) Haematologica , vol.95 , Issue.SUPPL. 2
    • Borchmann, P.1    Diehl, V.2    Goergen, H.3
  • 15
    • 84888811392 scopus 로고    scopus 로고
    • Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma
    • Andre MP, Reman O, Federico M, et al. Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. ASH Annual Meeting Abstracts 2012;120:549
    • (2012) ASH Annual Meeting Abstracts , vol.120 , pp. 549
    • Andre, M.P.1    Reman, O.2    Federico, M.3
  • 16
    • 84888785814 scopus 로고    scopus 로고
    • Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 Cycles ABVD. Results of the UK NCRI RAPID trial
    • Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 Cycles ABVD. Results of the UK NCRI RAPID trial. ASH Annual Meeting Abstracts 2012;120:547
    • (2012) ASH Annual Meeting Abstracts , vol.120 , pp. 547
    • Radford, J.1    Barrington, S.2    Counsell, N.3
  • 17
    • 77957945999 scopus 로고    scopus 로고
    • Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial
    • Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-206
    • (2010) J Clin Oncol , vol.28 , pp. 4199-4206
    • Eich, H.T.1    Diehl, V.2    Gorgen, H.3
  • 18
    • 33744829443 scopus 로고    scopus 로고
    • Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial
    • Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. ASH Annual Meeting Abstracts 2005;106:813
    • (2005) ASH Annual Meeting Abstracts , vol.106 , pp. 813
    • Ferme, C.1    Divine, M.2    Vranovsky, A.3
  • 19
    • 84860626866 scopus 로고    scopus 로고
    • Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial
    • von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-13
    • (2012) J Clin Oncol , vol.30 , pp. 907-913
    • Von Tresckow, B.1    Plutschow, A.2    Fuchs, M.3
  • 20
    • 84863011979 scopus 로고    scopus 로고
    • ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma
    • Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399-408
    • (2012) N Engl J Med , vol.366 , pp. 399-408
    • Meyer, R.M.1    Gospodarowicz, M.K.2    Connors, J.M.3
  • 21
    • 0026439199 scopus 로고
    • Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
    • Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84
    • (1992) N Engl J Med , vol.327 , pp. 1478-1484
    • Canellos, G.P.1    Anderson, J.R.2    Propert, K.J.3
  • 22
    • 0037007678 scopus 로고    scopus 로고
    • Long-term follow-up of Hodgkin's disease trial
    • Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-18
    • (2002) N Engl J Med , vol.346 , pp. 1417-1418
    • Canellos, G.P.1    Niedzwiecki, D.2
  • 23
    • 71849109593 scopus 로고    scopus 로고
    • Long-term follow-up of survival in Hodgkin's lymphoma
    • Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med 2009;361:2390-1
    • (2009) N Engl J Med , vol.361 , pp. 2390-2391
    • Canellos, G.P.1    Niedzwiecki, D.2    Johnson, J.L.3
  • 24
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3
  • 25
    • 71049118685 scopus 로고    scopus 로고
    • Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
    • Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
    • (2009) J Clin Oncol , vol.27 , pp. 4548-4554
    • Engert, A.1    Diehl, V.2    Franklin, J.3
  • 26
    • 19944428790 scopus 로고    scopus 로고
    • A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
    • Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-31
    • (2005) Ann Oncol , vol.16 , pp. 124-131
    • Ballova, V.1    Ruffer, J.U.2    Haverkamp, H.3
  • 27
    • 84884822211 scopus 로고    scopus 로고
    • Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: An analysis of the German Hodgkin study group
    • Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin study group. J Clin Oncol 2013;31:2819-24
    • (2013) J Clin Oncol , vol.31 , pp. 2819-2824
    • Wongso, D.1    Fuchs, M.2    Plutschow, A.3
  • 28
    • 84860833364 scopus 로고    scopus 로고
    • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial
    • Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
    • (2012) Lancet , vol.379 , pp. 1791-1799
    • Engert, A.1    Haverkamp, H.2    Kobe, C.3
  • 29
    • 59949089090 scopus 로고    scopus 로고
    • ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
    • Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11
    • (2009) J Clin Oncol , vol.27 , pp. 805-811
    • Federico, M.1    Luminari, S.2    Iannitto, E.3
  • 30
    • 79960583495 scopus 로고    scopus 로고
    • ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
    • Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12
    • (2011) N Engl J Med , vol.365 , pp. 203-212
    • Viviani, S.1    Zinzani, P.L.2    Rambaldi, A.3
  • 31
    • 84878399823 scopus 로고    scopus 로고
    • ABVD (8 cycles) versus BEACOPP (4 escalated cycles → 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial
    • Carde PP, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles → 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): first results of EORTC 20012 Intergroup randomized phase III clinical trial. ASCO Meeting Abstracts 2012;30:8002
    • (2012) ASCO Meeting Abstracts , vol.30 , pp. 8002
    • Carde, P.P.1    Karrasch, M.2    Fortpied, C.3
  • 32
    • 84883050177 scopus 로고    scopus 로고
    • Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: A systematic review and network meta-analysis
    • Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14:943-52
    • (2013) Lancet Oncol , vol.14 , pp. 943-952
    • Skoetz, N.1    Trelle, S.2    Rancea, M.3
  • 33
    • 84926296446 scopus 로고    scopus 로고
    • Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkińs lymphoma patients with positive positron emission tomography after two courses of chemotherapy: Preliminary results of the IIL HD-0801 study
    • Abstract 016
    • Zinzani PL, Bonfichi M, Rossi G, et al. Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkińs lymphoma patients with positive positron emission tomography after two courses of chemotherapy: preliminary results of the IIL HD-0801 study. Haematologica 2013;98:Abstract 016
    • (2013) Haematologica , pp. 98
    • Zinzani, P.L.1    Bonfichi, M.2    Rossi, G.3
  • 34
    • 84892146425 scopus 로고    scopus 로고
    • Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL/FIL HD0607 clinical trial
    • Gallamini A, Rossi A, Patti C, et al. Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL/FIL HD0607 clinical trial. ASH Annual Meeting Abstracts 2012;120:550
    • (2012) ASH Annual Meeting Abstracts , vol.120 , pp. 550
    • Gallamini, A.1    Rossi, A.2    Patti, C.3
  • 35
    • 84888138217 scopus 로고    scopus 로고
    • Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study
    • Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
    • (2013) Lancet Oncol , vol.14 , pp. 1348-1356
    • Younes, A.1    Connors, J.M.2    Park, S.I.3
  • 36
    • 84900794661 scopus 로고    scopus 로고
    • Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: Interim results of a randomized phase II study
    • Borchmann P, Eichenauer DA, Plütschow A, et al. Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Blood 2013;122:4344
    • (2013) Blood , vol.122 , pp. 4344
    • Borchmann, P.1    Eichenauer, D.A.2    Plütschow, A.3
  • 37
    • 79951890275 scopus 로고    scopus 로고
    • Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
    • Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074-80
    • (2010) J Clin Oncol , vol.28 , pp. 5074-5080
    • Josting, A.1    Muller, H.2    Borchmann, P.3
  • 38
    • 33846925670 scopus 로고    scopus 로고
    • Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma
    • Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35-41
    • (2007) Haematologica , vol.92 , pp. 35-41
    • Santoro, A.1    Magagnoli, M.2    Spina, M.3
  • 39
    • 0035253827 scopus 로고    scopus 로고
    • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
    • Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23
    • (2001) Blood , vol.97 , pp. 616-623
    • Moskowitz, C.H.1    Nimer, S.D.2    Zelenetz, A.D.3
  • 40
    • 84898410834 scopus 로고    scopus 로고
    • A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: Final results after early trial discontinuation
    • von Tresckow B, Skotnicki A, Lisukov I, et al. A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Blood 2013;122:4648
    • (2013) Blood , vol.122 , pp. 4648
    • Von Tresckow, B.1    Skotnicki, A.2    Lisukov, I.3
  • 41
    • 24644460669 scopus 로고    scopus 로고
    • Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group
    • Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005;23:5052-60
    • (2005) J Clin Oncol , vol.23 , pp. 5052-5060
    • Engert, A.1    Ballova, V.2    Haverkamp, H.3
  • 42
    • 84876515821 scopus 로고    scopus 로고
    • ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials
    • Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:1522-9
    • (2013) J Clin Oncol , vol.31 , pp. 1522-1529
    • Boll, B.1    Gorgen, H.2    Fuchs, M.3
  • 43
    • 83455220148 scopus 로고    scopus 로고
    • Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
    • Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011;118:6292-8
    • (2011) Blood , vol.118 , pp. 6292-6298
    • Boll, B.1    Bredenfeld, H.2    Gorgen, H.3
  • 44
    • 84862734110 scopus 로고    scopus 로고
    • Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: The SHIELD study
    • Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012;119:6005-15
    • (2012) Blood , vol.119 , pp. 6005-6015
    • Proctor, S.J.1    Wilkinson, J.2    Jones, G.3
  • 45
    • 33947612578 scopus 로고    scopus 로고
    • Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
    • Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007;48:570-6
    • (2007) Leuk Lymphoma , vol.48 , pp. 570-576
    • Kolstad, A.1    Nome, O.2    Delabie, J.3
  • 46
    • 84900831378 scopus 로고    scopus 로고
    • German Hodgkin study group phase i trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients
    • Boll B, Plütschow A, Fuchs M, et al. German Hodgkin study group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood 2013;122:3054
    • (2013) Blood , vol.122 , pp. 3054
    • Boll, B.1    Plütschow, A.2    Fuchs, M.3
  • 47
    • 84894356294 scopus 로고    scopus 로고
    • Relapsed Hodgkin lymphoma in older patients: A comprehensive analysis from the German Hodgkin Study Group
    • Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2013;31:4431-7
    • (2013) J Clin Oncol , vol.31 , pp. 4431-4437
    • Boll, B.1    Goergen, H.2    Arndt, N.3
  • 48
    • 39049195371 scopus 로고    scopus 로고
    • Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma
    • Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006;266-72
    • (2006) Hematology Am Soc Hematol Educ Program , pp. 266-272
    • Nogova, L.1    Rudiger, T.2    Engert, A.3
  • 49
    • 84861813756 scopus 로고    scopus 로고
    • Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
    • Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589-97
    • (2012) J Natl Compr Canc Netw , vol.10 , pp. 589-597
    • Hoppe, R.T.1    Advani, R.H.2    Ai, W.Z.3
  • 50
    • 27144479926 scopus 로고    scopus 로고
    • Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)
    • Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005;16:1683-7
    • (2005) Ann Oncol , vol.16 , pp. 1683-1687
    • Nogova, L.1    Reineke, T.2    Eich, H.T.3
  • 51
    • 73949125030 scopus 로고    scopus 로고
    • Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up
    • Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136-41
    • (2010) J Clin Oncol , vol.28 , pp. 136-141
    • Chen, R.C.1    Chin, M.S.2    Ng, A.K.3
  • 52
    • 80054835220 scopus 로고    scopus 로고
    • Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
    • Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-5
    • (2011) Blood , vol.118 , pp. 4363-4365
    • Eichenauer, D.A.1    Fuchs, M.2    Pluetschow, A.3
  • 53
    • 80055074730 scopus 로고    scopus 로고
    • Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
    • Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585-90
    • (2011) Blood , vol.118 , pp. 4585-4590
    • Savage, K.J.1    Skinnider, B.2    Al-Mansour, M.3
  • 54
    • 38649125204 scopus 로고    scopus 로고
    • Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group
    • Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-9
    • (2008) J Clin Oncol , vol.26 , pp. 434-439
    • Nogova, L.1    Reineke, T.2    Brillant, C.3
  • 55
    • 84873064941 scopus 로고    scopus 로고
    • Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP
    • Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts 2010;116:2812
    • (2010) ASH Annual Meeting Abstracts , vol.116 , pp. 2812
    • Fanale, M.A.1    Lai, C.-M.2    McLaughlin, P.3
  • 56
    • 38049162295 scopus 로고    scopus 로고
    • Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
    • Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-11
    • (2008) Blood , vol.111 , pp. 109-111
    • Schulz, H.1    Rehwald, U.2    Morschhauser, F.3
  • 57
    • 84877912785 scopus 로고    scopus 로고
    • High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
    • Karuturi M, Hosing C, Fanale M, et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant 2013;19:991-4
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 991-994
    • Karuturi, M.1    Hosing, C.2    Fanale, M.3
  • 58
    • 4143080389 scopus 로고    scopus 로고
    • Solid tumors in patients treated for Hodgkin's disease: A report from the German Hodgkin Lymphoma Study Group
    • Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004;15:1079-85
    • (2004) Ann Oncol , vol.15 , pp. 1079-1085
    • Behringer, K.1    Josting, A.2    Schiller, P.3
  • 59
    • 84897530655 scopus 로고    scopus 로고
    • Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group
    • Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123:1658-64
    • (2014) Blood , vol.123 , pp. 1658-1664
    • Eichenauer, D.A.1    Thielen, I.2    Haverkamp, H.3
  • 60
    • 80755127111 scopus 로고    scopus 로고
    • Second cancer risk after chemotherapy for Hodgkin's lymphoma: A collaborative British cohort study
    • Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096-104
    • (2011) J Clin Oncol , vol.29 , pp. 4096-4104
    • Swerdlow, A.J.1    Higgins, C.D.2    Smith, P.3
  • 61
    • 33847348995 scopus 로고    scopus 로고
    • Late cardiotoxicity after treatment for Hodgkin lymphoma
    • Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-86
    • (2007) Blood , vol.109 , pp. 1878-1886
    • Aleman, B.M.1    Van Den Belt-Dusebout, A.W.2    De Bruin, M.L.3
  • 62
    • 67649646579 scopus 로고    scopus 로고
    • Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma
    • De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-37
    • (2009) J Natl Cancer Inst , vol.101 , pp. 928-937
    • De Bruin, M.L.1    Dorresteijn, L.D.2    Van'T Veer, M.B.3
  • 63
    • 58049219093 scopus 로고    scopus 로고
    • Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group
    • Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980-7
    • (2008) J Clin Oncol , vol.26 , pp. 5980-5987
    • Morschhauser, F.1    Brice, P.2    Ferme, C.3
  • 64
    • 84891073765 scopus 로고    scopus 로고
    • The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG)
    • Hartmann S, Eichenauer DA, Plutschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013;122:4246-52
    • (2013) Blood , vol.122 , pp. 4246-4252
    • Hartmann, S.1    Eichenauer, D.A.2    Plutschow, A.3
  • 65
    • 84900823372 scopus 로고    scopus 로고
    • Nodular lymphocyte predominant Hodgkin's lymphoma-evaluation of a scoring system to predict recurrences
    • Abstract 145
    • Panjwani P, Epari S, Sengar M, et al. Nodular lymphocyte predominant Hodgkin's lymphoma-evaluation of a scoring system to predict recurrences. Haematologica 2013;98:Abstract 145
    • (2013) Haematologica , pp. 98
    • Panjwani, P.1    Epari, S.2    Sengar, M.3
  • 66
    • 33749262442 scopus 로고    scopus 로고
    • Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
    • Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006;77:387-94
    • (2006) Eur J Haematol , vol.77 , pp. 387-394
    • Visco, C.1    Nadali, G.2    Vassilakopoulos, T.P.3
  • 67
    • 84872928596 scopus 로고    scopus 로고
    • Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
    • Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013;88:113-15
    • (2013) Am J Hematol , vol.88 , pp. 113-115
    • Sauer, M.1    Plutschow, A.2    Jachimowicz, R.D.3
  • 68
    • 84879750415 scopus 로고    scopus 로고
    • Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial
    • Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 2013;121:3547-53
    • (2013) Blood , vol.121 , pp. 3547-3553
    • Kanakry, J.A.1    Li, H.2    Gellert, L.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.